Reply to: Reflections on HBV Adaptation and Immune Interactions: Insights and Future Directions [0.03%]
对《关于乙型肝炎病毒适应性和免疫相互作用的思考：洞察与未来方向》一文的回应
Maximilian Damagnez,Andreas Walker,Jörg Timm
Maximilian Damagnez
Revisiting the use of albumin in patients with cirrhosis - trial design matters [0.03%]
重新审视白蛋白在肝硬化患者中的应用-试验设计很重要
Ann T Ma,Adrià Juanola,Cristina Solé et al.
Ann T Ma et al.
Both the timing of the measurement and the adjustment of the portal pressure gradient (PPG) after TIPS implantation are important [0.03%]
TIPS置入后测量时机和门静脉压力梯度(PPG)的调整都非常重要
Alexander Zipprich,Philipp Reuken,Andreas Stallmach et al.
Alexander Zipprich et al.
Personalized risk assessment of advanced liver fibrosis in patients with MASLD [0.03%]
伴有代谢相关脂肪性肝病的患者肝纤维化风险评估个性化研究
Arne Åsberg,Ingrid Alsos Lian,Lena Løfblad et al.
Arne Åsberg et al.
Developing splice-switching oligonucleotides for urea cycle disorder using an integrated diagnostic and therapeutic platform [0.03%]
使用整合诊断和治疗平台为尿素循环障碍开发剪接切换寡核苷酸
Jin Rong Ow,Eri Imagawa,Feng Chen et al.
Jin Rong Ow et al.
Backgrounds & aims: Citrin deficiency (CD) is an autosomal recessive urea cycle disorder caused by biallelic loss-of-function variants in the SLC25A13 gene, leading to life-threatening hyperammonemia and hypoglycemia. Var...
A phase III randomised study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer [0.03%]
一项关于一线NUC-1031/顺铂与吉西他滨/顺铂治疗晚期胆道肿瘤的III期随机研究
Jennifer J Knox,Mairéad G McNamara,Igor S Bazin et al.
Jennifer J Knox et al.
Background and aims: The previous first-line standard of care for advanced biliary tract cancer (aBTC), gemcitabine/cisplatin, had modest efficacy. NUC-1031 is a phosphoramidate modification of gemcitabine. We report fina...
Expression of concern to "Nitric oxide mimics transcriptional and post-translational regulation during α-Tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes" [J Hepatol. 2011 Jul;55(1):133-44] [0.03%]
对“Nitric oxide mimics transcriptional and post-translational regulation during α-Tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes”[J Hepatol. 2011 Jul;55(1):133-44]的关切表达
From the Editor's Desk. [0.03%]
主编观点。
Philip Newsome,Frank Tacke,Heiner Wedemeyer et al.
Philip Newsome et al.
Reply to: Correspondence on 'Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer' [0.03%]
对《关于“晚期胆道癌ctDNA和组织基因组分析的一致性”》一文的回复
Sohyun Hwang,Seonjeong Woo,Chan Kim et al.
Sohyun Hwang et al.